USCarePharm Files PCT International Patent for Composition Improving Lipid Metabolism Disorders
[Korea Financial Economy News – Reporter Kim Garam]
USCarePharm Co., Ltd. has announced the filing of a PCT (Patent Cooperation Treaty) international patent application for a composition proven to improve lipid metabolism disorders.

The PCT system simplifies and unifies the process of filing patents abroad, allowing applicants to seek protection in up to 153 member countries through a single application.

The patented composition is the result of years of research and development, and has demonstrated multiple functional effects, including:

Reduction of blood triglycerides and cholesterol
Inhibition of adipocyte (fat cell) differentiation
Improvement of fatty liver conditions
Reduction of visceral fat

A company representative stated,

“USCarePharm possesses a wide range of functional natural ingredients developed through its proprietary UMAP (USCarePharm Material Advancement Platform), which enhances the bioavailability and efficacy of natural materials. We are committed to growing as a specialized R&D-driven company in the field of functional natural products.”

They added,

“This PCT application is highly meaningful as it extends our intellectual property rights internationally. We are also actively pursuing technology export opportunities based on this composition.”

USCarePharm continues to focus on the development of high-performance skincare products using advanced natural materials derived through UMAP. The company has also launched its functional derma-cosmetics brand, LLEAFILL®, which is available both domestically and internationally through distributors and online channels.

Further details on LLEAFILL products can be found through the official brand store.

Source: Korea Financial Economy News (www.kfenews.co.kr)